A perpetual loser at the high stakes game of Alzheimer's research, Roche concedes another amyloid flop - Endpoints News
6/15/2022 12:00:00 AM2 years 10 months ago
by John Carroll
by John Carroll
The amyloid beta theory that has driven billions of dollars in failed Alzheimer’s research has taken yet another body blow. Roche — and specifically its big sub Genentech — conceded defeat overnight for its closely watched Phase II API-ADAD trial of crenezuma…
A House appropriations subcommittee advanced via voice vote a new spending bill for the FDA yesterday, offering $3.6 billion in discretionary funding (i.e. not user fees), which is a 10% increase fro… [+504 chars]
full article...